Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260M

Author: Benzinga Newsdesk | May 01, 2024 07:10am

Posted In: TGTX